Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2019 ASCO Annual Meeting
Oncology Conference Multimedia
View more videos >>
OncLive News Network On Location: In Chicago Tuesday, June 4
Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer
Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma
Oncology Conference Articles
Larotrectinib Effective in TRK+ Pediatric Cancers and CNS Tumors
The efficacy of larotrectinib is supported in distinct patient populations with
fusion cancer—specifically pediatric patients and adult or pediatric patients with brain metastases or primary central nervous system tumors.
Neratinib Combo Improves PFS in HER2+ Breast Cancer
Neratinib combined with capecitabine reduced the risk of disease progression or death by 24% compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who received at least 2 prior lines of HER2-targeted therapy.
Capivasertib Combined With Fulvestrant Improves PFS in ER+ Breast Cancer
Adding the Akt inhibitor capivasertib to fulvestrant led to a more than doubling of progression-free survival compared with fulvestrant alone in patients with endocrine-resistant estrogen receptor-positive advanced breast cancer.
Margetuximab Superior to Trastuzumab on PFS in HER2-Positive Metastatic Breast Cancer Carriers of CD16A-F Allele
Margetuximab, a novel Fc-engineered HER2-targeted antibody, improved progression-free survival compared with trastuzumab in patients with pretreated HER2-positive metastatic breast cancer in the open-label phase III SOPHIA clinical trial.
Acalabrutinib Combo Induces High Responses in CLL
Simultaneous targeting of Bruton’s tyrosine kinase and the CD20 antigen led to overall responses in more than 90% of patients with chronic lymphocytic leukemia, including untreated and relapsed/refractory disease.
Olaparib Extends PFS, Hits High Response in Confirmatory BRCA+ Ovarian Cancer Trial
The PARP inhibitor olaparib reduced the risk of disease progression or death by 38% versus chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA1/2-mutated ovarian cancer who received at least 2 prior lines of chemotherapy.
Chemo-Free Combo Significantly Improves PFS in Previously Untreated CLL
The addition of venetoclax to obinutuzumab reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia.
Niraparib/Bevacizumab Combo Active in Recurrent Ovarian Cancer
A chemotherapy-free doublet for platinum-sensitive recurrent ovarian cancer more than doubled progression-free survival as compared with single-agent PARP inhibitor.
New Therapies Intriguing for Elusive Targets in NSCLC
Two new therapies are showing encouraging findings for patients with NSCLC with either
exon 20 insertions, raising hope that 2 hard-to-target driver alterations may soon have an associated targeted treatment.
AMG 510 Active in KRAS+ NSCLC
The investigational KRAS
inhibitor AMG 510 achieved a 50% response rate in patients with KRAS
-positive advanced non–small cell lung cancer, according to results from a phase I study presented at the 2019 ASCO Annual Meeting.
Atezolizumab Boosts Survival in Patients With NSCLC, Liver Mets
Patients with non–small cell lung cancer and baseline liver metastases had improved progression-free survival and overall survival with the addition of immunotherapy to bevacizumab and a chemotherapy doublet.
New Targeted Therapies Show Promise for METex14-Altered NSCLC
Two highly selective MET inhibitors, tepotinib and capmatinib showed promising clinical activity in the first- and second-line treatment of patients with MET exon 14-altered advanced non–small cell lung cancer.
Ramucirumab/Erlotinib Significantly Improves PFS in Frontline EGFR+ NSCLC
Adding ramucirumab to erlotinib reduced the risk of disease progression or death by over 40% versus erlotinib alone as a frontline treatment for patients with EGFR-positive NSCLC.
FDA Streamlines Expanded Access for Oncology Agents
The FDA has unveiled what it describes as a pilot “concierge service” for oncologists and patients seeking information and assistance with expanded access to investigational therapies.
Preoperative Immunotherapy Sends Positive Signals in 2 NSCLC Studies
Neoadjuvant immunotherapy demonstrated substantial activity with a favorable toxicity profile in findings from 2 studies of patients with operable early-stage non–small cell lung cancer reported at the 2019 ASCO Annual Meeting.
Nearly Two-Thirds of Gynecologic Oncologists Report Being Sexually Harassed
More than 70% of female gynecologic oncologists in the United States and more than half of male practitioners have experienced sexual harassment in training or practice, according to results from a survey conducted by the Society of Gynecologic Oncology.
Laparoscopic Surgery Found to Be Noninferior to Open Surgery Method for CRC Liver Metastases
Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.
Broader Trial Criteria Would Almost Double Eligibility in Advanced NSCLC
A broader set of clinical trial eligibility criteria proposed by the American Society of Clinical Oncology and Friends of Cancer Research would nearly double the number of patients with advanced non-small cell lung cancer available for enrollment.
Enfortumab Vedotin Produces Responses in Patients With Advanced Urothelial Carcinoma
Enfortumab vedotin induced responses in 44% of patients with locally advanced or metastatic urothelial cancer, including 12% experiencing a complete response to treatment.
Isatuximab Triplet Significantly Improves PFS in Myeloma
Adding isatuximab to pomalidomide and low-dose dexamethasone led to a greater than 40% reduction in the risk of disease progression or death compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Subcutaneous Daratumumab Shows Similar Efficacy, Greater Convenience in Phase III Myeloma Trial
A subcutaneous flat-dose version of daratumumab demonstrated noninferior efficacy with a reduction in the treatment burden compared with the original intravenous formulation of the anti-CD38 monoclonal antibody for patients with relapsed/refractory multiple myeloma.
High TMB Metastatic Breast Cancer Responds to Pembrolizumab Monotherapy
Examination of a cohort of patients with metastatic breast cancer and high mutational burden who were enrolled in the phase II Targeted Agent and Profiling Utilization Registry basket study shows that pembrolizumab monotherapy has antitumor activity in this population of heavily pretreated patients.
Lurbinectedin Shows Promise as Single-Agent in Second-Line SCLC
Lurbinectedin monotherapy achieved an overall response rate of 35.2% as a second-line treatment for patients with small cell lung cancer, according to findings from a phase II basket trial presented at the 2019 ASCO Annual Meeting.
Maintenance Olaparib Improves PFS in BRCA+ Metastatic Pancreatic Cancer
Maintenance therapy with olaparib significantly improved progression-free survival compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.
Enzalutamide Increases Survival in mHSPC Over Other Anti-Androgens
Almost 80% of men with metastatic hormone-sensitive prostate cancer treated with enzalutamide plus standard of care (SOC) were alive after 3 years compared with 72% of patients who received a different non-steroidal anti-androgen plus SOC.
Alarm Sounded Over Multiple Myeloma Outcomes Versus Socioeconomics
Higher income was associated with significantly greater probability of survival for patients with multiple myeloma, according to authors of a study they performed to call attention to the need to address socioeconomic disparities that influence treatment outcomes.
Medicaid Expansion Helps Reduce Racial Disparities in Access to Cancer Care
The expansion of Medicaid nearly eliminated racial disparities in time to cancer treatment.
ACA Improved Ovarian Cancer Diagnosis and Time to Treatment
Pre-Medicare-aged women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis after passage of the Affordable Care Act than before.
Open Source System Debuts for EHR Data Sharing
A consortium of cancer care institutions released details on a prototype system designed to link electronic health record systems to provide a source of real-world patient information to guide research and improve cancer treatment.
New Strategies Needed for TKI Resistance in EGFR+ Lung Cancer
The development of tyrosine kinase inhibitors has revolutionized the treatment of
-mutant non–small cell lung cancer in recent years, but new strategies are needed to overcome resistance mechanisms that promote disease recurrence.
Apalutamide Extends Survival in Metastatic Castration-Sensitive Prostate Cancer
Adding apalutamide to androgen deprivation therapy (ADT) reduced the risk of the death by 33% in patients with metastatic castration-sensitive prostate cancer compared with ADT alone.
Frontline Pembrolizumab Induces Comparable OS, Fewer AEs in Advanced GEJ Cancer
Frontline pembrolizumab demonstrated non-inferior overall survival compared with standard chemotherapy among patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.
Ribociclib Improves Survival by Nearly 30% for Premenopausal Women With Advanced Breast Cancer
Ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared 46.0% for placebo and endocrine therapy in premenopausal women with HR-positive, HER2-negative advanced breast cancer.
Pembrolizumab OS Rates Continue to Impress in NSCLC at 5 Years
After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.
ASCO 2019: Oncology Leaders Select Top Studies
Within the week, thousands of abstracts spanning a multitude of tumor types will be presented at the 2019 ASCO Annual Meeting, many of which will lead to practice-changing implications for oncologists.
Entrectinib Achieves Strong Responses in Pediatric Cancers, Including CNS Tumors
Entrectinib induced objective responses in 100% of pediatric patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions or mutations.
Pediatric Precision Medicine Approach Proven Possible in Pediatric MATCH Trial
About a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration of pathway in the screening protocol of the National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial.
Lower-Dose Chemotherapy Regimen Benefits Elderly, Frail Patients with Gastroesophageal Cancer
A lower dose of oxaliplatin and capecitabine had comparable efficacy and minimized adverse events in elderly and frail patients with advanced gastroesophageal cancer.
Lenalidomide Reduces Risk for Smoldering Multiple Myeloma Progression
In patients with smoldering multiple myeloma, lenalidomide induced a 72% reduction in the risk for progression to symptomatic disease at 3 years.
Low-Fat Diet Could Reduce Risk of Death From Breast Cancer
Women who eat a balanced, low-fat diet and daily portions of vegetables, fruit, and grains have a 21% lower risk of dying from breast cancer.
OncLive News Network On Location: ASH 2019 Day 3
Dr. Coleman on Findings From the AZURE Trial for Breast Cancer Treatment
Dr. Murthy on HER2CLIMB Trial Results in HER2+ Breast Cancer
Prostate Cancer Treatment Options Expand With ADT Combinations
Tucatinib Boosts Survival in HER2+ Breast Cancer, FDA Submission Imminent
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.